Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
ZYLOPRIM
Generic name / active ingredient
allopurinol
Dosage-form class
Oral tablets: 100 mg, 200 mg and 300 mg (as listed in the current U.S. label; this dossier separately displays three 90-tablet bottle panels)
Route
Oral
Record reviewed
2026-08-21

Copy from the pack in hand

Source-linked reading points

  • Check ZYLOPRIM, allopurinol, 100/200/300 mg, the actual NDC, oral-tablet form and target market together. Milligrams are the labelled amount in this exact tablet, not an answer to how many tablets anyone should take; a shared generic name, another strength or another dosage form cannot be self-converted from a number.
  • The current label describes shape, imprint and functional scoring for the three tablet presentations. These are product-identity clues, not a way to authenticate a photograph or permission to self-split, make up or adjust use. If the actual pack, prescription or swallowing situation differs, take the pack to a pharmacist or prescribing team.
  • The label links HLA-B*58:01 with risk of severe allopurinol hypersensitivity and explains that the meaning of testing depends on timing around treatment and population context. This page neither recommends universal screening nor turns a positive, negative or existing genetic report into a conclusion about starting, continuing, stopping or switching; take the original report, actual pack and complete medicine list to a professional.
  • The current label flags thiazide diuretics, ampicillin, amoxicillin, azathioprine and mercaptopurine among co-medications requiring particular review. It is not a checklist for self-stopping, adding, spacing or switching products; give prescription medicines, OTC products, supplements and recent changes together to a pharmacist or clinician. With a new rash, blisters, mouth/eye discomfort, fever, lip/facial swelling, breathing difficulty or another acute severe concern, prioritise local urgent medical and prescribing-team pathways rather than self-managing from a webpage or self-restarting treatment.

Reviewed presentation examples — compare every field

  • 100 mg per tablet; 90-tablet bottleNDC 70199-031-90
  • 200 mg per tablet; 90-tablet bottleNDC 70199-032-90
  • 300 mg per tablet; 90-tablet bottleNDC 70199-033-90

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-21
Source record
1 clickable primary-source entry point is listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image